Enjoy complimentary customisation on priority with our Enterprise License!
The canine atopic dermatitis market share is expected to increase by USD 319.37 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.75%.
This canine atopic dermatitis market research report extensively covers market segmentation by product (antihistamines, glucocorticoids, progestational compounds, and others) and geography (North America, Europe, Asia, and ROW).
The canine atopic dermatitis market report also offers information on several market vendors, including Bioceltix Spolka Akcyjna, Ceva Sante Animale, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Novartis AG, Toray Industries Inc., Vetoquinol UK Ltd., Vimian Group AB, Virbac, and Zoetis Inc. among others. Furthermore, this report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches.
Download the Free Report Sample to Unlock the Canine Atopic Dermatitis Market Size for the Forecast Period and Other Important Statistics
The increase in pet humanization is notably driving the canine atopic dermatitis market growth, although factors such as stringent global regulatory requirements may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the canine atopic dermatitis industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Canine Atopic Dermatitis Market Driver
Key Canine Atopic Dermatitis Market Trend
Key Canine Atopic Dermatitis Market Challenge
This canine atopic dermatitis market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the canine atopic dermatitis market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the canine atopic dermatitis market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the canine atopic dermatitis market encompasses successful business strategies deployed by the key vendors. The canine atopic dermatitis market is fragmented and the vendors are deploying growth strategies such as low pricing strategies and strengthening their customer base in local or regional markets to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The canine atopic dermatitis market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the canine atopic dermatitis market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
For more insights on the market share of various regions Request for a FREE sample now!
37% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the canine atopic dermatitis market in North America. Market growth in this region will be slower than the growth of the market in Europe.
The large interest in pet ownership will facilitate the canine atopic dermatitis market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
Studies have found that SAR-CoV-2, the virus responsible for COVID-19, can be spread from humans to pets in some situations. Hence, a few veterinary diagnostic laboratories have developed COVID-19 diagnostics tests for dogs and cats, but these are not available as routine tests as yet. Moreover, the adoption of pets in the region has increased during the COVID-19 pandemic. Thus, the increasing demand for pets will drive market growth during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The canine atopic dermatitis market share growth by the antihistamines segment will be significant during the forecast period. Antihistamines are defined as drugs that are commonly used to treat allergies. They are also beneficial for controlling skin allergies in dogs. Hence, antihistamine drugs are highly cost-effective, easily available, and are the most commonly prescribed type of medication for the treatment of allergies, which will fuel the growth of this segment during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the canine atopic dermatitis market size and actionable market insights on post COVID-19 impact on each segment.
Canine Atopic Dermatitis Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.75% |
Market growth 2022-2026 |
$ 319.37 million |
Market structure |
Fragmented |
YoY growth (%) |
4.03 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 37% |
Key consumer countries |
US, Canada, UK, Brazil, Germany, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Bioceltix Spolka Akcyjna, Ceva Sante Animale, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Novartis AG, Toray Industries Inc., Vetoquinol UK Ltd., Vimian Group AB, Virbac, and Zoetis Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Product
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.